Read our Recent Headlines


August 28 Biotech Update

I was busy for a day and the market does great but I come back and we have a gap lower. Sorry. In all seriousness, however, the snap back rally.

August 26 Biotech Update

The market had a rough day yesterday where the rally from the “lows” earlier in the week faded at the end of the day. That is never a good sign.

August 25 Biotech Update

Despite ending the day down significantly, it actually felt like a good day. I wanted to post a real quick and short note as from now on Tuesday and Thursday.

August 24 Biotech Update

Wow. What a start to the week. In terms of news there was not much but we had an incredible flash crash in the large caps at the open. From.

August 21 Biotech Update

So it is obviously getting rough and we got our first peeks of panic yesterday. Most everyone seems to think that the worst is yet to come and I would.

August 20 Biotech Update

Another gap lower but the market remains in a rut refusing to breakdown or breakout. As I have said before, 2015 has been a year of churn and that is.

August 19 Biotech Update

Not much has changed sector wide since I last wrote but we did have a trade play out, although not quite the way I expected. I want to talk about.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!